Arkema SA (AKE)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 54.45 |
|---|---|
| 52-week range | 48.30 – 67.05 |
| Return, 1 month / 3 months | −5.3% / −1.6% |
| Return, 1 year / 3 years | +9.7% / −23.9% |
| Trend | Below its 200-day average |
| RSI (14) | 40 |
| Volatility (1 year) | 32.4% |
| Worst drawdown (1 year) | -22.8% |
| Average daily value traded | 10.43M EUR |
| Dividend yield | 6.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Arkema is a French specialty chemicals and advanced materials company based near Paris. It makes specialty polymers, adhesives, coating resins, and performance additives, along with products used in batteries and lightweight materials. Its customers are industrial manufacturers and formulators in construction, automotive, electronics, packaging, and consumer goods, and it supplies these markets across Europe, the Americas, and Asia through its own plants and technical teams.
The shares are listed on the Euronext Paris in France under the code AKE, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Arkema SA (AKE) trades on the Euronext Paris in France. It last closed at EUR 54.45 on 23 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 73 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 9.7% and over the last three months it fell 1.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | -3.4% | ||
| From 52-week high | -16.8% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -1.6% | ||
| 6-month return | -6.3% | ||
| 12-month return, skipping the last month | 15.8% | ||
| Stability (higher is calmer) | 70 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 32.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.8% | ||
| Liquidity | 90 · Strong | Trades actively. | |
| Average daily value traded | 10.43M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 70 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 6.6% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −3.0% |
|---|---|
| 1 month | −5.3% |
| 3 months | −1.6% |
| 6 months | −6.3% |
| 1 year | +9.7% |
| 3 years | −23.9% |
| 5 years | −41.4% |
Signals
| 50-day / 200-day average | 57.10 / 56.38 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.22 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 25 May 2026 | EUR 3.6000 |
| 26 May 2025 | EUR 3.6000 |
| 17 May 2024 | EUR 3.5000 |
| 15 May 2023 | EUR 3.4000 |
| 23 May 2022 | EUR 3.0000 |
| 26 May 2021 | EUR 2.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.